Novartis Ag

Nicole Haubst

Seth Alexander Ettenberg

Winfried Elis

Andrew Paul Garner

Elizabeth Anne Reisinger Sprague

Engin Toksoz

Daniel Huang

Jean-Michel Rene Rondeau

Gino Van Heeke

Hans-Peter Knopf

Christian Kunz

Danforth Miller

Tiancen Hu

Matthew John Meyer

Xizhong Huang

David Jenkins

Christian Carsten Silvester Kunz

Konstantin Petropoulos

Matthew John Edwards

Qing Sheng

Kapil Gupta

Barbara Andlauer

Rene Hemmig

David Bryant Batt

Bijan Etemad-Gilbertson

Joy Gispati Ghosh

Michael Stefanidakis

Chad Eric Bigelow

Stephen Hedrick Poor

Nina Moker

Ganesh Rajan Iyer

Seth Ettenberg

Christian Carsten Kunz

Michael Zbigniew Twarog

Nalini Velamur Rangaswamy

Yubin Qiu

Andrew Anh Nguyen

Shawn Michael Hanks

Kirk Lee Clark

James Edgar Chastain

Ana Maria Carrion

Gino Anselmus Van Heeke

The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules

This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).

Antibodies for epidermal growth factor receptor 3 (HER3)

The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.

The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Antibody drug conjugates

The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Growing community of inventors

Munich, Germany

Nicole Haubst